Jundishapur Journal of Microbiology

Published by: Kowsar

Detection of Synergistic Antimicrobial Activities of Ceftaroline, Telavancin, Daptomycin, and Vancomycin Against Methicillin-Resistant Staphylococcus aureus Strains in Intensive Care Units

Laser Şanal 1 , * , Neziha Yılmaz 2 , Hatice Uludag 3 , Reyhan Öztürk 4 , Süha Sen 5 and Salih Cesur 6
Authors Information
1 Microbiology Laboratory, Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey
2 Medical Microbiology Department, Bozok University, Yozgat, Turkey
3 Human Tissue and Cell Laboratory, Yasam Bank, Ankara, Turkey
4 Infectious Diseases Department, Keçiören Training and Research Hospital, Ankara, Turkey
5 Infectious Diseases Department, Beytepe Murat Erdi Eker Hospital, Ankara, Turkey
6 Infectious Diseases Department, Ankara Training and Research Hospital, Ankara, Turkey
Article information
  • Jundishapur Journal of Microbiology: November 2018, 11 (11); e66445
  • Published Online: October 17, 2018
  • Article Type: Research Article
  • Received: January 18, 2018
  • Revised: July 19, 2018
  • Accepted: August 1, 2018
  • DOI: 10.5812/jjm.66445

To Cite: Şanal L, Yılmaz N, Uludag H, Öztürk R, Sen S, et al. Detection of Synergistic Antimicrobial Activities of Ceftaroline, Telavancin, Daptomycin, and Vancomycin Against Methicillin-Resistant Staphylococcus aureus Strains in Intensive Care Units, Jundishapur J Microbiol. 2018 ; 11(11):e66445. doi: 10.5812/jjm.66445.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Thompson DS. Methicillin-resistant Staphylococcus aureus in a general intensive care unit. J R Soc Med. 2004;97(11):521-6. doi: 10.1258/jrsm.97.11.521. [PubMed: 15520145]. [PubMed Central: PMC1079644].
  • 2. Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J. 2002;78(921):385-92. [PubMed: 12151652]. [PubMed Central: PMC1742438].
  • 3. Hanberger H, Walther S, Leone M, Barie PS, Rello J, Lipman J, et al. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: Results from the EPIC II study. Int J Antimicrob Agents. 2011;38(4):331-5. doi: 10.1016/j.ijantimicag.2011.05.013. [PubMed: 21798720].
  • 4. Landrum ML, Neumann C, Cook C, Chukwuma U, Ellis MW, Hospenthal DR, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA. 2012;308(1):50-9. doi: 10.1001/jama.2012.7139. [PubMed: 22760291].
  • 5. Erdem H, Dizbay M, Karabey S, Kaya S, Demirdal T, Koksal I, et al. Withdrawal of Staphylococcus aureus from intensive care units in Turkey. Am J Infect Control. 2013;41(11):1053-8. doi: 10.1016/j.ajic.2013.01.041. [PubMed: 23663858].
  • 6. Denis O, Deplano A, Nonhoff C, Hallin M, De Ryck R, Vanhoof R, et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother. 2006;50(8):2680-5. doi: 10.1128/AAC.00272-06. [PubMed: 16870758]. [PubMed Central: PMC1538679].
  • 7. Hasan R, Acharjee M, Noor R. Prevalence of vancomycin resistant Staphylococcus aureus (VRSA) in methicillin resistant S. aureus (MRSA) strains isolated from burn wound infections. Ci Ji Yi Xue Za Zhi. 2016;28(2):49-53. doi: 10.1016/j.tcmj.2016.03.002. [PubMed: 28757721]. [PubMed Central: PMC5442891].
  • 8. Kaur DC, Chate SS. Study of antibiotic resistance pattern in methicillin resistant Staphylococcus aureus with special reference to newer antibiotic. J Glob Infect Dis. 2015;7(2):78-84. doi: 10.4103/0974-777X.157245. [PubMed: 26069428]. [PubMed Central: PMC4448330].
  • 9. Ribes S, Pachon-Ibanez ME, Dominguez MA, Fernandez R, Tubau F, Ariza J, et al. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides. Eur J Clin Microbiol Infect Dis. 2010;29(11):1361-7. doi: 10.1007/s10096-010-1007-y. [PubMed: 20680368]. [PubMed Central: PMC3128719].
  • 10. Dhand A, Sakoulas G. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther. 2014;36(10):1303-16. doi: 10.1016/j.clinthera.2014.09.005. [PubMed: 25444563].
  • 11. Sueke H, Kaye SB, Neal T, Hall A, Tuft S, Parry CM. An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51(8):4151-5. doi: 10.1167/iovs.09-4839. [PubMed: 20335613].
  • 12. Barber KE, Werth BJ, Rybak MJ. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother. 2015;70(2):505-9. doi: 10.1093/jac/dku378. [PubMed: 25246437]. [PubMed Central: PMC4291233].
  • 13. Werth BJ, Barber KE, Ireland CE, Rybak MJ. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2014;58(6):3177-81. doi: 10.1128/AAC.00088-14. [PubMed: 24663016]. [PubMed Central: PMC4068431].
  • 14. Silva LV, Araujo MT, Santos KR, Nunes AP. Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains. Mem Inst Oswaldo Cruz. 2011;106(1):44-50. [PubMed: 21340354].
  • 15. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. 2016. Available from: http://www.eucast.org.
  • 16. Mitsugui CS, Tognim MC, Cardoso CL, Carrara-Marroni FE, Botelho Garcia L. In vitro activity of polymyxins in combination with beta-lactams against clinical strains of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2011;38(5):447-50. doi: 10.1016/j.ijantimicag.2011.06.012. [PubMed: 21872449].
  • 17. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603-61. doi: 10.1128/CMR.00134-14. [PubMed: 26016486]. [PubMed Central: PMC4451395].
  • 18. Raygada JL, Levine DP. Methicillin-resistant Staphylococcus aureus: A growing risk in the hospital and in the community. Am Health Drug Benefits. 2009;2(2):86-95. [PubMed: 25126276]. [PubMed Central: PMC4115307].
  • 19. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40(8):1914-8. [PubMed: 8843303]. [PubMed Central: PMC163439].
  • 20. Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad. Indian J Med Res. 2011;134(5):704-8. doi: 10.4103/0971-5916.91001. [PubMed: 22199111]. [PubMed Central: PMC3249970].
  • 21. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med. 2006;166(19):2138-44. doi: 10.1001/archinte.166.19.2138. [PubMed: 17060545].
  • 22. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755-71. doi: 10.1093/cid/cir935. [PubMed: 22302374].
  • 23. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: A global analysis 2004-2009. Int J Antimicrob Agents. 2011;37(3):219-24. doi: 10.1016/j.ijantimicag.2010.10.029. [PubMed: 21239146].
  • 24. Chadha P, Mariano N, LaBombardi V, Segal-Maurer S, Urban C. In vitro activities of mupirocin, tigecycline, ceftaroline, vancomycin, linezolid and daptomycin in clinical isolates of methicillin-resistant Staphylococcus aureus by E-test methodology. Open J Med Microbiol. 2015;5(1):12-6. doi: 10.4236/ojmm.2015.51002.
  • 25. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother. 2000;44(4):1062-6. [PubMed: 10722513]. [PubMed Central: PMC89814].
  • 26. Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob Agents Chemother. 2013;57(7):3178-81. doi: 10.1128/AAC.00484-13. [PubMed: 23629712]. [PubMed Central: PMC3697312].
  • 27. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrob Agents Chemother. 2015;59(3):1811-4. doi: 10.1128/AAC.04616-14. [PubMed: 25561335]. [PubMed Central: PMC4325802].
  • 28. Leonard SN, Vidaillac C, Rybak MJ. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2009;53(7):2928-33. doi: 10.1128/AAC.01544-08. [PubMed: 19414568]. [PubMed Central: PMC2704675].
  • 29. Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. Antimicrob Agents Chemother. 2015;59(9):5529-34. doi: 10.1128/AAC.00773-15. [PubMed: 26124162]. [PubMed Central: PMC4538535].
  • 30. Maselli DJ, Fernandez JF, Whong CY, Echevarria K, Nambiar AM, Anzueto A, et al. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia. Infect Drug Resist. 2012;5:43-51. doi: 10.2147/IDR.S17433. [PubMed: 22355258]. [PubMed Central: PMC3278208].
  • 31. Bilmen FB, Turhanoglu, M . Antimicrobial activity of ceftaroline and ceftobiprole tested against MRSA isolates from Turkey, in 2016. IOSR J Pharm Biol Sci (IOSR-JPBS). 2016;11(1):52-6. doi: 10.9790/3008-11145256.
  • 32. Gaikwad V, Gohel T, Panickar S, Chincholkar V, Mangalkar S. In vitro activity of ceftaroline: A novel antibiotic against methicillin-resistant Staphylococcus aureus. Indian J Pathol Microbiol. 2016;59(4):496-8. doi: 10.4103/0377-4929.191798. [PubMed: 27721280].
  • 33. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40(7):1058-60. doi: 10.1086/428616. [PubMed: 15825002].
  • 34. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36(10):1317-33. doi: 10.1016/j.clinthera.2014.05.061. [PubMed: 25017183].
  • 35. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, et al. beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56(12):6192-200. doi: 10.1128/AAC.01525-12. [PubMed: 22985884]. [PubMed Central: PMC3497165].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments